Indirect comparison of ixekizumab versus risankizumab for up to 12 weeks of treatment in patients with moderate-to-severe psoriasis

Introduction: Psoriasis is a common chronic inflammatory skin disorder, and the time needed to achieve clinically significant improvement is important to patients. Ixekizumab (IXE), an anti-interleukin (IL)-17A monoclonal antibody, is approved for the treatment of moderate-to-severe psoriasis and has demonstrated superior efficacy over ustekinumab (UST) and placebo (PBO) in clinical trials. Due to lack of head-to-head trials of IXE with certain comparators of interest, we indirectly compared psoriasis clinical trial efficacy data between IXE and selective IL-23 inhibitors.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research